Facing escalating trade tensions and looming tariffs under former U.S. President Donald Trump’s policy trajectory, pharmaceutical giant Merck & Co. $MRK has announced a $1 billion investment in a new biomanufacturing facility in Delaware. The plant will play a pivotal role in reinforcing the company’s domestic production capacity, particularly for its flagship oncology treatment, Keytruda.

On Monday, shares of Akeso Inc. $9926.HK plunged by a staggering 19% during trading in Hong Kong. This significant decline occurred after the company released preliminary data on its new cancer medication, which, despite showcasing certain advantages, failed to meet investors' expectations. The drop in stock price coincided with news of notable achievements by the drug relative to a traditional treatment, yet this very comparison led to inflated anticipations.